RankAlpha logo
Back to Rankings

PEPG

PepGenF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
PEPG vs peer average
20/100
PEPG vs. peer average (F vs. C)
Grade spread
A 2 · B 2 · C 2 · D 1 · F 3
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

RNA is the first available peer comparator.

Avidity is a direct DM1 operating comparator because PepGen identifies del-desiran/AOC 1001 as a Phase 3 clinical program competing against PepGen's DM1 candidate, making RNA the clearest category benchmark for speed and perceived efficacy leadership [#10-K-2026-03-04].

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerRNAAtrium Therapeutics
PEPG
PepGen
RNA
Atrium Therapeutics
Grade
F
A
Momentum
97
30
Value
41
59
Sentiment
9
100
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Constructive
Open Side-by-Side ComparisonCompare all

Grade position vs RNA

PEPG / RNA
Grade Position
Below peers
PEPG vs. peer average (F vs. C)
20/100
Momentum
97
PEPG
Value
41
RNA
Sentiment
9
RNA

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs PEPG
1
RNA
RNA
A
100/100
-4
2
TRDA
TRDA
C
60/100
-2
3
SIGA
SIGA Technologies Inc Common
F
20/100
Even
4
NERV
Minerva Neurosciences Inc Common
B
80/100
-3
5
CRDL
Cardiol Therapeutics Inc Class A Common
F
20/100
Even
RNA is the first peer returned for this comparison set.